- Home
- Hematology
- Ravulizumab in HSCT TMA Evaluating Event-Free Survival in a Phase 3 Trial
4w3 min read
Medical Article
Introduction (1) Atypical haemolytic uraemic syndrome (atypical HUS) is a rare complement-mediated thrombotic microangiopathy (TMA) defined by thrombocytopenia, microangiopathic haemolytic anaemia (MAHA), and progressive renal injury (1). Complement pathway dysregulation caused by acquired or familial abnormalities in complement factor H (CFH), com

Ravulizumab in HSCT TMA Evaluating Event-Free Survival in a Phase 3 Trial
13 Reached
Similar Content

Pancytopenia, a rare presentation of hyperthyroidism
832 Reached2 Comments

Safe Ramadan Practices during COVID-19 - WHO Guidance
6540 Reached8 Comments3 Likes

How Physicians Should Manage Stress?
35339 Reached151 Comments202 Likes

Managing Meconium Aspiration Syndrome in Infants
9817 Reached7 Comments8 Likes

Infant with Congenital Diaphragmatic Hernia (CDH)
6983 Reached14 Comments8 Likes
